Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
TBPH Stock Chart & Stats
$20.61
-$0.06(-0.65%)
At close: 4:00 PM EST
$20.61
-$0.06(-0.65%)
Day’s Range― - ―
52-Week Range$7.90 - $20.69
Previous CloseN/A
Volume28.33K
Average Volume (3M)445.74K
Market Cap
$1.04B
Enterprise Value$472.77M
Total Cash (Recent Filing)$329.68M
Total Debt (Recent Filing)$44.59M
Price to Earnings (P/E)36.6
Beta0.94
Next Earnings
Mar 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding50,672,432
10 Day Avg. Volume424,926
30 Day Avg. Volume445,735
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)2.62
Price to Sales (P/S)7.14
P/FCF Ratio-38.73
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue5.89
Enterprise Value/Gross Profit9.40
Enterprise Value/Ebitda-18.29
Forecast
1Y Price Target
$28.40Price Target Upside37.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partner Product Sales And Milestone RevenueStrong demand and favorable net pricing for partnered respiratory products are driving collaboration revenue and are likely to trigger sales-related milestone payments that improve the company's cash visibility.
Physician Prescribing Intent In MSAHigh intent from neurologists and cardiologists to prescribe a once-daily option for multiple system atrophy patients with neurogenic orthostatic hypotension suggests meaningful uptake potential if ampreloxetine demonstrates consistent safety and efficacy.
Regulatory Pathway And Trial DesignA randomized-withdrawal Phase 3 design enriched for high responders, combined with FDA alignment on endpoints and preparations for an expedited filing, increases the probability of a favorable regulatory review for ampreloxetine.
Bears Say
Class Safety And Efficacy ConcernsWidespread limitations and safety issues with current treatments for neurogenic orthostatic hypotension, including concerns about supine hypertension and long-term use, could prompt greater regulatory and payer scrutiny for new therapies and complicate adoption.
Outcome Dependency On MilestonesHeavy reliance on regulatory approvals and sales-triggered milestone payments makes the financial outlook highly dependent on trial results and partner commercial performance, increasing downside risk for the stock.
Trial Recruitment And Execution RiskLogistical hurdles causing slow enrollment in the CYPRESS trial may delay data readouts and heighten operational risk for ampreloxetine's development timeline.
Theravance Biopharma News
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $7.90 and its highest was $20.69 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is $1.04B.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Mar 02, 2026 which is in 45 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on Nov 10, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.198.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is 1.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 50,672,432 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went up 22.679%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in TBPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theravance Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.40 (37.80% Upside)
$28.40 (37.80% Upside)
Blogger Sentiment
Bearish
TBPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 910.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.61%
12-Months-Change
Fundamentals
Return on Equity
14.03%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
TBPH Company Deck
TBPH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial position with record sales and profitability for YUPELRI, significant progress in ampreloxetine's clinical trials, and upcoming milestone achievements for Trelegy. Despite minor operational challenges, the overall outlook remains positive with a focus on future growth and strategic objectives.View all TBPH earnings summariesTBPH Stock 12 Month Forecast
Average Price Target
$28.40
▲(37.80% Upside)
Technical Analysis
Anavex Life Sciences
―
Maravai Lifesciences Holdings
―
Terns Pharmaceuticals
―
Nanobiotix
―
Day One Biopharmaceuticals
―
Ownership Overview
Currently, No data available
---